“`html
Obagi Medical (NASDAQ: WALD) showcased compelling new clinical data at the American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago, held from November 13-16, 2025. The presentation highlighted advancements in both injectable and scalp serum technologies, signaling potential growth drivers for the company.
Obagi presented pivotal non-inferiority data and promising 3‑month scalp serum results at ASDS, supporting regulatory momentum.
The pivotal randomized multicenter trial showed Obagi® saypha® ChIQ™ met non-inferiority versus Juvéderm Voluma® XC for midface augmentation and nasolabial fold improvement, with high patient satisfaction and a robust safety profile across diverse skin types; the abstract earned a top 10 oral presentation at the ASDS meeting on November 13–16, 2025. This outcome provides a clear clinical data point that supports the product’s competitive positioning pending FDA review.
Key dependencies and risks include the ongoing regulatory review status (under FDA review) and the fact that the scalp serum results are interim at 3 months, so durability and long‑term safety remain unconfirmed. The claim of category‑leading “capabilities” and proprietary technologies should be viewed as manufacturer framing until detailed endpoint data, statistical margins, and full safety tables are available.
Items to watch: final FDA determination for Obagi® saypha® ChIQ™ and release of full pivotal study data (patient numbers, primary endpoint results, and adverse event rates) and longer follow‑up for Nu‑Cil® BioStim™ beyond 3 months. Expect these disclosures or regulatory milestones within the next regulatory review cycle and subsequent conference publications or journal submission timelines.
11/16/2025 – 01:02 AM
Obagi’s saypha ChIQ Data Earns Top 10 Cosmetic Abstract Honors
NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) — Obagi Medical, a key player in the physician-dispensed skincare and aesthetics market under Waldencast plc (NASDAQ: WALD), unveiled noteworthy research at the recent ASDS Annual Meeting. The presented data encompassed both injectable hyaluronic acid (HA) fillers and scalp serum innovations.
A standout presentation featured Dr. Sue Ellen Cox discussing a pivotal study comparing two HA fillers for midface augmentation and nasolabial fold improvement. “As an investigator in this pivotal study, I was pleased that the data was recognized as one of the top 10 abstracts and selected for an oral presentation,” noted Dr. Cox. “The data highlights the compelling results of the Obagi saypha ChIQ pivotal study and shows the potential of the product to provide high-level satisfaction for patients seeking long-lasting, natural-looking results.”
The randomized, multicenter trial demonstrated that Obagi saypha ChIQ achieved non-inferiority when compared to Juvéderm Voluma XC in terms of effectiveness and safety. Patient satisfaction remained high across a range of skin types, suggesting broad applicability.
In addition, interim data was presented for Obagi Nu-Cil BioStim Scalp Serum, indicating improvements in scalp health and hair appearance after three months of use, signaling potential for growth in the increasingly competitive haircare market.
Researchers also introduced a novel framework for evaluating HA filler crosslinking technologies, touting the capabilities of the Obagi injectable line. This research appears geared towards bolstering the brand’s positioning within the highly technical field of aesthetic injectables.
Drew Fine, U.S. General Manager, Professional Channel at Obagi Medical, commented, “Obagi Medical’s commitment to advancing dermatologic science and driving innovation is reflected in the data shared across our skincare and injectable portfolio at the recent ASDS meeting. New products with proven quality, a well-established safety profile, and high patient satisfaction are critical to expanding the aesthetic injectable market. The selection of the Obagi saypha ChIQ abstract as one of the top 10 for oral presentation highlights the powerful data supporting the new Obagi injectable.”
The Nu-Cil BioStim Scalp Serum leverages Obagi’s expertise in skin health by extending its “skin-first” philosophy to the scalp. The BioStim Complex, incorporating biotin, amino acids, peptides, and 18 essential nutrients, aims to boost scalp health, fortify hair follicles, and strengthen strands.
Obagi saypha ChIQ, developed by Croma-Pharma GmbH, employs proprietary MACRO Core Technology for a stable 3D HA matrix. Currently under FDA review, it aims to deliver natural-looking results with consistent gel distribution and a predictable injection profile. Obagi’s saypha MagIQ recently secured FDA approval, creating a potential pathway to approval for the ChIQ formulation. The technological comparison between the MACRO Core Technology and other crosslinking technologies will be essential for market differentiation.
Obagi Medical is a recognized leader in advanced skincare, offering research-backed solutions for diverse skin concerns.
Waldencast’s ambition involves a global beauty and wellness platform, developing conscious brands, and leveraging operational scale. Obagi Medical and Milk Makeup represent the first steps in this strategy.
Croma-Pharma GmbH specializes in minimally invasive aesthetic medicine, producing HA syringes and offering a comprehensive aesthetics portfolio.
Investors should note forward-looking statements involve significant risks and uncertainties. FDA approval for Saypha ChIQ products, commercial launch success, geopolitical events, market conditions, and Waldencast’s strategic initiatives are all critical factors potentially impacting results. The competitive landscape in both dermal fillers and hair growth treatments is intense, requiring continued innovation and strong marketing to succeed.
What did Obagi (WALD) announce at the ASDS meeting on Nov 13–16, 2025?
Obagi shared pivotal trial data where saypha ChIQ was non-inferior to Juvéderm Voluma XC for midface augmentation and reported interim 3-month results for Nu-Cil BioStim Scalp Serum.
What does the saypha ChIQ non-inferiority result mean for WALD shareholders?
The study showed non-inferiority versus Juvéderm Voluma XC with high patient satisfaction and robust safety, and the abstract was a top 10 oral presentation at ASDS; saypha ChIQ is under FDA review.
What were the Nu-Cil BioStim scalp serum results reported by Obagi (WALD) at ASDS?
Interim 3-month data indicated reported improvements in scalp health and hair appearance from the ongoing Nu-Cil BioStim study.
Is Obagi saypha ChIQ FDA approved and how does that affect WALD?
Obagi saypha ChIQ is currently under FDA review; a related product, saypha MagIQ, has received FDA approval.
Who presented the pivotal saypha ChIQ data for Obagi (WALD) at ASDS 2025?
Dr. Sue Ellen Cox presented the pivotal trial and the abstract was selected as a top 10 oral presentation.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/12950.html
